NICE 'conditional approvals' to replace England's Cancer Drugs Fund
This article was originally published in Scrip
Executive Summary
A new "managed access fund" for financing oncology drugs conditionally approved by NICE could provide a proper long-term remedy to England's poor uptake of oncology products if it can replace the Cancer Drugs Fund, something that has become a soggy sticking plaster. But although the plans may offer companies hope of market access for future drugs, there is still uncertainty over what will happen to patients and drugs failed by the current system, like Eisai's Halaven.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.